Glucose-Dependent Insulinotropic Polypeptide

GIPpeptide

GIP dysregulation associates with metabolic dysfunction and accelerated coronary atherosclerosis in Type 1 MI.

Pathway placement

Cascade stepOff-pathway / systemic markers

Confidencelow

RationaleMetabolic/endocrine hormone; role in coronary calcification reflects systemic metabolic and risk factors.

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresType-II-associated

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-66.7

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationmag 2

2anemia / acute blood lossn/a

3hypovolemia / dehydrationn/a

4tachyarrhythmian/a

5hypoxemia / respiratory failuren/a

6hypertensive emergencyn/a

7high-demand / peri-operative stressn/a

Coverage: 1/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 18 supporting references. See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)

Collection tube

K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)

Method / principle

Competitive/sandwich immunoassay or LC-MS/MS

Reagent / substrate

Anti-peptide antibody; or isotope-labeled internal standard (MS)

Platform

Immunoassay / LC-MS/MS

Turnaround · availability

Send-out / research · Research-grade